Cystic Fibrosis Clinical Management and Therapeutic Approaches

Cystic fibrosis is a multisystem genetic disorder caused by mutations in the CFTR gene, leading to impaired chloride and bicarbonate transport across epithelial surfaces. Clinical management centres on early diagnosis through newborn screening and newborn genotype confirmation, followed by proactive interventions to preserve lung function, maintain nutritional status and prevent complications. Standard care encompasses airway clearance techniques, inhaled and systemic antibiotics to suppress chronic infection, pancreatic enzyme replacement and optimised dietary regimens. Advances in understanding CFTR biology have yielded targeted therapies—the so-called modulators—that address the underlying protein defect. These include potentiators that enhance channel opening, correctors that promote folding and trafficking, amplifiers that increase CFTR expression and read-through agents that suppress premature termination codons. Complementary approaches under investigation range from gene therapy using viral and non-viral vectors to anti-inflammatory strategies and microbiome modulation. The integration of these modalities within a multidisciplinary framework has transformed life expectancy and quality of life for people with cystic fibrosis, heralding an era of precision medicine.

Research from Nature Portfolio

Recent studies have introduced engineered suppressor tRNAs fine-tuned to restore translation across premature termination codons in the CFTR gene. Administered via lipid nanoparticles by intravenous and intratracheal routes, these sequences promote functional CFTR protein expression in patient-derived epithelia and animal models without affecting native termination sites. This strategy offers a high-safety profile and the potential for broad applicability across various nonsense mutations causing cystic fibrosis.

Cystic Fibrosis Clinical Management and Therapeutic Approaches publication trend

The graph below shows the total number of articles in cystic fibrosis clinical management and therapeutic approaches across all publications each year (not limited to Nature Index journals).

Technical terms

CFTR (Cystic Fibrosis Transmembrane Conductance Regulator): An epithelial anion channel whose dysfunction underlies cystic fibrosis.

Premature termination codon (PTC): A mutation that introduces an early stop signal in mRNA, truncating protein translation.

Suppressor tRNA (sup-tRNA): Engineered transfer RNA designed to bypass PTCs, restoring correct amino acid incorporation.

Lipid nanoparticle (LNP): A lipid-based carrier for nucleic acids, enhancing delivery to target tissues.

Potentiator: A small molecule that increases the gating activity of CFTR channels at the cell surface.

Corrector: A compound that improves CFTR folding and trafficking to the cell membrane.

References

1. Engineered tRNAs suppress nonsense mutations in cells and in vivo. Nature (2023).
2. Structure-based discovery of CFTR potentiators and inhibitors. Cell (2024).
3. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Frontiers in Pharmacology (2020).